ArticlePloS one2018
Controlling epidemics with transmissible vaccines.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Design of field trials for the evaluation of transmissible vaccines in animal populations.PLoS computational biology · 2025Article
- A non-transmissible live attenuated SARS-CoV-2 vaccine.Molecular therapy : the journal of the American Society of Gene Therapy · 2023Article
- Inferring the disruption of rabies circulation in vampire bat populations using a betaherpesvirus-vectored transmissible vaccine.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Rabies in a postpandemic world: resilient reservoirs, redoubtable riposte, recurrent roadblocks, and resolute recidivism.Animal diseases · 2023Review
- Article
- Asian-Origin Approved COVID-19 Vaccines and Current Status of COVID-19 Vaccination Program in Asia: A Critical Analysis.Vaccines · 2021Article
- Designing transmissible viral vaccines for evolutionary robustness and maximum efficiency.Virus evolution · 2021Article
- Health Literacy of the Inland Population in Mitigation Phase 3.2 of the COVID-19 Pandemic in Portugal: A Descriptive Cross-Sectional Study.Portuguese journal of public health · 2020Article
- Epidemiology and biology of a herpesvirus in rabies endemic vampire bat populations.Nature communications · 2020Article
- Evolution and containment of transmissible recombinant vector vaccines.Evolutionary applications · 2019Article
- A general framework for modelling the impact of co-infections on pathogen evolution.Journal of the Royal Society, Interface · 2019Article
- Transmissible vaccines in heterogeneous populations: Implications for vaccine design.One health (Amsterdam, Netherlands) · 2019Article
- A little goes a long way: Weak vaccine transmission facilitates oral vaccination campaigns against zoonotic pathogens.PLoS neglected tropical diseases · 2019Article
- Precision public health to inhibit the contagion of disease and move toward a future in which microbes spread health.BMC infectious diseases · 2019Review
- Recombinant transmissible vaccines will be intrinsically contained despite the ability to superinfect.Expert review of vaccinesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
As the density of human and domestic animal populations increases, the threat of localized epidemics and global pandemics grows. Although effective vaccines have been developed for a number of threatening pathogens, manufacturing and disseminating vaccines in the face of a rapidly spreading epidemic or pandemic remains a formidable challenge. One potentially powerful solution to this problem is the use of transmissible vaccines. Transmissible vaccines are capable of spreading from one individual to another and are currently being developed for a range of infectious diseases. Here we develop and analyze mathematical models that allow us to quantify the benefits of vaccine transmission in the face of an imminent or ongoing epidemic. Our results demonstrate that even a small amount of vaccine transmission can greatly increase the rate at which a naïve host population can be protected against an anticipated epidemic and substantially reduce the size of unanticipated epidemics if vaccination is initiated shortly after pathogen detection. In addition, our results identify key biological properties and implementation practices that maximize the impact of vaccine transmission on infectious disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.